Quotient (NASDAQ:QTNT) Now Covered by StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Quotient (NASDAQ:QTNTGet Rating) in a note issued to investors on Saturday. The firm set a “hold” rating on the stock.

Several other brokerages also recently issued reports on QTNT. Cowen lowered their price target on Quotient from $9.00 to $3.00 and set an “outperform” rating for the company in a report on Wednesday, June 29th. Cowen decreased their price objective on shares of Quotient from $9.00 to $3.00 and set an “outperform” rating for the company in a research report on Wednesday, June 29th. Finally, BTIG Research reduced their price target on shares of Quotient from $9.00 to $1.50 and set a “buy” rating on the stock in a research report on Wednesday, June 29th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Quotient has an average rating of “Moderate Buy” and a consensus price target of $2.25.

Quotient Price Performance

Shares of NASDAQ:QTNT opened at $0.21 on Friday. The business’s 50 day simple moving average is $0.23 and its 200-day simple moving average is $0.51. The firm has a market capitalization of $21.58 million, a price-to-earnings ratio of -0.16 and a beta of 2.76. Quotient has a 12 month low of $0.16 and a 12 month high of $3.19.

Quotient (NASDAQ:QTNTGet Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The company had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $9.40 million. On average, equities analysts anticipate that Quotient will post -0.69 earnings per share for the current year.

Insiders Place Their Bets

In other Quotient news, Director Prondzynski Heino Von bought 700,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were purchased at an average price of $0.20 per share, with a total value of $140,000.00. Following the completion of the acquisition, the director now directly owns 1,405,879 shares of the company’s stock, valued at approximately $281,175.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Quotient news, Director Prondzynski Heino Von bought 700,000 shares of the business’s stock in a transaction on Thursday, September 15th. The shares were purchased at an average price of $0.20 per share, with a total value of $140,000.00. Following the completion of the acquisition, the director now directly owns 1,405,879 shares of the company’s stock, valued at approximately $281,175.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Zubeen Shroff purchased 4,666,666 shares of the company’s stock in a transaction on Friday, June 24th. The stock was purchased at an average price of $0.30 per share, for a total transaction of $1,399,999.80. Following the purchase, the director now directly owns 11,995,740 shares of the company’s stock, valued at approximately $3,598,722. The disclosure for this purchase can be found here. Insiders have acquired 5,718,140 shares of company stock valued at $1,615,354 over the last quarter. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On Quotient

Several large investors have recently made changes to their positions in the company. ProShare Advisors LLC increased its stake in shares of Quotient by 70.5% in the fourth quarter. ProShare Advisors LLC now owns 17,142 shares of the company’s stock valued at $45,000 after purchasing an additional 7,086 shares during the period. Clearbridge Investments LLC increased its stake in shares of Quotient by 0.8% during the first quarter. Clearbridge Investments LLC now owns 4,255,908 shares of the company’s stock valued at $5,107,000 after acquiring an additional 33,409 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Quotient during the first quarter valued at approximately $48,000. State Street Corp increased its stake in shares of Quotient by 8.1% during the first quarter. State Street Corp now owns 1,502,911 shares of the company’s stock valued at $1,803,000 after acquiring an additional 112,013 shares during the period. Finally, Walleye Capital LLC increased its stake in shares of Quotient by 246.3% during the fourth quarter. Walleye Capital LLC now owns 192,730 shares of the company’s stock valued at $499,000 after acquiring an additional 137,071 shares during the period. Institutional investors and hedge funds own 86.84% of the company’s stock.

Quotient Company Profile

(Get Rating)

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.

Read More

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.